Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00435669
Status:
COMPLETED
Last Update Posted:
2009-01-22
First Post:
2007-02-14
Brief Title:
A Phase I Study to Determine Absorption Distribution Metabolism and Elimination of a Single Radiolabeled Dose of Brivanib BMS-582664
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Mass Balance Pharmacokinetics and Metabolism of 14CBMS-582664 Prodrug of BMS-540215 in Subjects With Advanced or Metastatic Solid Tumors
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to determine the mass balance pharmacokinetics metabolism and routes and extent of elimination of BMS-582664
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None